Clinical Trial Update: A Phase I/II Study of Sunitinib and Dacarbazine [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II trial evaluating the combination of sunitinib and dacarbazine for melanoma was terminated (status: TERMINATED).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• DTIC-Dome (dacarbazine)
• Sutent (sunitinib)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Melanoma | Phase 1, Phase 2 | Status: TERMINATED